News | March 17, 2010

SPIRIT Results Show Continued Positive Results Market-Leading Stent

March 17, 2010 – New data released at the American College of Cardiology Scientific Session this week showed continued positive clinical results for the Xience V everolimus-eluting coronary stent.

Four-year results from the SPIRIT II trial were presented by Yoshinobu Onuma, M.D., Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. In key clinical outcomes such as heart attack, repeat procedure at the target lesion or death, XIENCE V demonstrated a consistent reduction in all these areas out to five years compared to the TAXUS paclitaxel-eluting coronary stent. The SPIRIT II four-year data also demonstrated that there were no new stent thrombosis events for XIENCE V between two and four years.

Data presentations by James Hermiller, M.D., St. Vincent’s Hospital, Indianapolis, Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, Cincinnati, and Upendra Kaul, M.D., director of cardiology, Fortis Hospital, Noida. India, demonstrated that in complex lesion subsets, XIENCE V exhibited low event rates to the overall population.

Dr. Hermiller presented pooled results on small vessel subsets from the SPIRIT III and SPIRIT IV trials. At one year, XIENCE V outperformed TAXUS in small vessel patients, demonstrating a significant reduction in major adverse cardiac events (4.5 vs. 7.9 percent) and a significant reduction in target lesion failure (4.4 vs. 7.9 percent). There was also a significant 56 percent reduction in target lesion revascularization (TLR) with XIENCE V compared to TAXUS.

Dr. Kereiakes presented a pooled analysis from the SPIRIT III and SPIRIT IV trials, comparing XIENCE V and TAXUS in patients undergoing multivessel stenting. At one year, treatment with XIENCE V resulted in significantly lower rates of adverse events than those treated with TAXUS.

Dr. Kaul presented one-year follow-up data on of complex lesion and patient subgroups from the SPIRIT V Registry. In this registry, XIENCE V achieved single-digit cardiac death, MI and TLR rates in highly complex patient and lesion subgroups such as diabetics, multiple lesions, small vessels, long lesions and bifurcation lesions.

Data on the cost effectiveness of XIENCE V vs. TAXUS were presented by David Cohen, M.D., director of Cardiovascular Research, St. Luke’s Mid-America Heart Institute, Kansas City, Mo. He used data from the SPIRIT IV trial, which found the superior clinical outcomes of XIENCE V had a better economic outcome for both the hospital and healthcare system. At one year, XIENCE V provided improved clinical outcomes and a lower overall medical cost, which saved about $150 to $450 per patient.

Abbott makes the XIENCE V stent (which is also sold under the name PROMUS by Boston Scientific). Boston Scientific produced the TAXUS stent, but discontinued production last fall to concentrate on its second generation TAXUS Liberte paclitaxel-eluting coronary stent.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init